Homepage
Author:
argenx SE
Posted Date:
June 3, 2026
argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026
argenx SE
June 3, 2026
argenx to Host Myositis R&D Webinar on June 23, 2026
argenx SE
May 28, 2026
argenx to Present at Upcoming Investor Conferences
argenx SE
May 27, 2026
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
argenx SE
May 8, 2026
argenx Reports First Quarter 2026 Financial Results and Provides Business Update
argenx SE
May 7, 2026
argenx to Present at BofA Securities 2026 Health Care Conference
argenx SE
May 6, 2026
argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer
argenx SE
May 6, 2026
argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
argenx SE
April 30, 2026
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
argenx SE
April 18, 2026
argenx announces Annual General Meeting of Shareholders on May 6, 2026
argenx SE
March 20, 2026
1
2
Next
